Clinical Trial Update: An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update reporting efficacy and safety of Risperidone long-acting injectable in schizophrenia-spectrum disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Drugs mentioned

• Risperidone long-acting injectable (Risperdal Consta) (Risperidone)

Snippet

Sponsor: Janssen-Cilag Ltd. | Conditions: Schizophrenia, Schizophreniform Disorder | Phase 4 | Status: COMPLETED | Results posted: 2013-07-25